# FDA recall D-145-2013

> **Watson Pharmaceuticals** · Class II · drug recall initiated 2012-12-18.

## Product

Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.

## Reason for recall

Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).

## Distribution

Nationwide and Puerto Rico

## Key facts

- **Recall number:** D-145-2013
- **Recalling firm:** Watson Pharmaceuticals
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2012-12-18
- **Report date:** 2013-02-13
- **Termination date:** 2014-07-30

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Parsippany, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-145-2013

## Citation

> AI Analytics. FDA recall D-145-2013. Retrieved 2026-05-25 from https://api.ai-analytics.org/recall/D-145-2013. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*